# Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis

> **NCT06374979** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Guttate Psoriasis

## Interventions

- **BIOLOGICAL:** Ixekizumab

## Key facts

- **NCT ID:** NCT06374979
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374979, "Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06374979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*